Potential Strategies and Biosafety Protocols Used for Dual-use Research on Highly Pathogenic Influenza Viruses

Overview

Journal Rev Med Virol

Publisher Wiley

Specialty Microbiology

Date 2012 Sep 19

PMID 22987727

Citations 1

Authors

Lanying Du

Ye Li

Jimin Gao

Yusen Zhou

Shibo Jiang

Affiliations

Soon will be listed here.

Abstract

Influenza A viruses (IAVs), particularly the highly pathogenic avian influenza H5N1, have posed a substantial threat to public health worldwide. Although the laboratory generation of the mutant influenza virus H5N1 with airborne transmissibility among mammals, which has been considered as a dual-use research, may benefit the development of effective vaccines and therapeutics against the emerging infectious agents, it may also pose threats to national biosecurity, laboratory biosafety, and/or public health. This review introduces the classification and characterization of IAVs, pinpoints historic pandemics and epidemics caused by IAVs, emphasizes the significance and necessity of biosafety, summarizes currently established biosafety-related protocols for IAV research, and provides potential strategies to improve biosafety protocols for dual-use research on the highly pathogenic avian influenza viruses and other emerging infectious agents.

Citing Articles

Biosecurity and biosafety in research on emerging pathogens.

Lu L, Liu Q, Jiang S Emerg Microbes Infect. 2015; 1(11):e44.

PMID: 26038411 PMC: 3630924. DOI: 10.1038/emi.2012.39.

References

Carrillo-Esper R . Statins in influenza: time for a controlled clinical study. Cir Cir. 2009; 77(5):351-2. View

Hunter P . H5N1 infects the biosecurity debate. Governments and life scientists are waking up to the problem of dual-use research. EMBO Rep. 2012; 13(7):604-7. PMC: 3388791. DOI: 10.1038/embor.2012.80. View

. Publishing risky research. Nature. 2012; 485(7396):5. DOI: 10.1038/485005a. View

Faden R, Karron R . Public health and biosecurity. The obligation to prevent the next dual-use controversy. Science. 2012; 335(6070):802-4. DOI: 10.1126/science.1219668. View

Butler D . Flu surveillance lacking. Nature. 2012; 483(7391):520-2. DOI: 10.1038/483520a. View

Fouchier R, Garcia-Sastre A, Kawaoka Y . Pause on avian flu transmission studies. Nature. 2012; 481(7382):443. DOI: 10.1038/481443a. View

Du L, Zhou Y, Jiang S . Research and development of universal influenza vaccines. Microbes Infect. 2010; 12(4):280-6. DOI: 10.1016/j.micinf.2010.01.001. View

Starbuck E . Mutant flu: preparing for a pandemic. Nature. 2012; 482(7386):470. DOI: 10.1038/482470a. View

Nordmann B . Issues in biosecurity and biosafety. Int J Antimicrob Agents. 2010; 36 Suppl 1:S66-9. DOI: 10.1016/j.ijantimicag.2010.06.025. View

10.

Taubenberger J . The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Arch Virol Suppl. 2005; (19):101-15. DOI: 10.1007/3-211-29981-5_9. View

11.

Jiang S, Li R, Du L, Liu S . Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell. 2011; 1(4):342-354. PMC: 4728157. DOI: 10.1007/s13238-010-0054-6. View

12.

Stott D, Kerr G, Carman W . Nosocomial transmission of influenza. Occup Med (Lond). 2002; 52(5):249-53. DOI: 10.1093/occmed/52.5.249. View

13.

Patterson K, Pyle G . The geography and mortality of the 1918 influenza pandemic. Bull Hist Med. 1991; 65(1):4-21. View

14.

Du L, Leung V, Zhang X, Zhou J, Chen M, He W . A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One. 2011; 6(1):e16555. PMC: 3029370. DOI: 10.1371/journal.pone.0016555. View

15.

Fouchier R, Munster V, Wallensten A, Bestebroer T, Herfst S, Smith D . Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol. 2005; 79(5):2814-22. PMC: 548452. DOI: 10.1128/JVI.79.5.2814-2822.2005. View

16.

Russell C, Jones T, Barr I, Cox N, Garten R, Gregory V . Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2009; 26 Suppl 4:D31-4. DOI: 10.1016/j.vaccine.2008.07.078. View

17.

Pavia A . Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits. Ann Intern Med. 2012; 156(6):463-5. DOI: 10.7326/0003-4819-156-6-201203200-00386. View

18.

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View

19.

Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R . Avian H5N1 influenza in cats. Science. 2004; 306(5694):241. DOI: 10.1126/science.1102287. View

20.

Fouchier R, Herfst S, Osterhaus A . Public health and biosecurity. Restricted data on influenza H5N1 virus transmission. Science. 2012; 335(6069):662-3. DOI: 10.1126/science.1218376. View